India’s radiopharmaceuticals market is expanding as cancer incidence, chronic disease diagnosis, and investment in nuclear medicine increase. The market was valued at USD 0.44 billion in 2024 and is projected to reach USD 1.06 billion by 2035, reflecting an estimated CAGR of 8.26%. 1087

Radiopharmaceuticals are radioactive compounds used in specialized diagnostic imaging and therapeutic applications. In oncology, they can support disease detection, staging, treatment planning, and targeted therapy. The growing use of PET and SPECT imaging is creating demand for reliable diagnostic radiopharmaceuticals in hospitals and imaging centers.

Oncology is the largest application segment, while cardiology is expected to grow rapidly. More cancer centers, improved access to nuclear imaging, and continued research into radioligand therapies are likely to strengthen the market. India’s healthcare system is also increasing its focus on precision medicine, where treatments and diagnostics are selected based on individual patient characteristics.

Local manufacturing capacity, radioisotope availability, skilled nuclear-medicine professionals, and cold-chain logistics will remain important to the industry’s development.

Read more: India Radiopharmaceuticals Market 1087

FAQs

Q1. What are radiopharmaceuticals used for?
They are used in specialized imaging and targeted therapeutic procedures, particularly in oncology, cardiology, and neurology.

Q2. Which application leads the Indian market?
Oncology leads because of the need for advanced cancer imaging and targeted treatment options.

Tags: India radiopharmaceuticals market, nuclear medicine, precision oncology, PET imaging, radioligand therapy